logo-loader

Destiny Pharma awaits key inflection point mid--2020 in its antimicrobial Phase 2b clinical trial

Published: 22:33 15 Jan 2020 GMT

Destiny Pharma (LON:DEST) CEO Neil Clark spoke with Proactive at the Biotech Showcase 2020 in San Francisco. The UK-based, clinical phase biotechnology company is focused on preventing post-surgical infection in a Phase 2b clinical trial with its lead asset. According to its website, Destiny is building a portfolio of antimicrobial drug products that to combat the threat of antimicrobial resistance (AMR).

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and...

on 2/5/23